The rise of Sildenafil initially drove a period of growth for pharma, but recent changes present a complicated outlook for shareholders. Lower-cost alternatives are eroding profits, and persistent patent challenges add https://jaysoncipu178930.dm-blog.com/41490795/viagra-and-pharma-a-volatile-bet